Pfizer Aktie News

When Pfizer was coming out of the COVID-induced growth phase in early 2024, I turned bullish alongside CEO Albert Bourla, effectively betting his pension on Pfizer stock. Since then, Pfizer has proven to be a drag on my portfolio returns, but I have found good enough reasons to remain bullish. One of the biggest drags on Pfizer stock has been rising investor concerns over Pfizer's ability to br...

Long-term bond yields persist despite pressure. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly reported in October, 2024. It's still true. Steven Wieting, strategist at CitiWealth, told Barron's that a growing div...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company's common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026. Pfizer is committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocati...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metasta...

Pfizer has been dismissed as a defendant in ​a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers ‌and executives of fixing generic drug prices.

David Denton's appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.

China has pulled ahead of Europe in pharmaceutical innovation and drug development, a senior Pfizer executive said on Tuesday.

Pfizer ​said on ‌Monday ​its ​drug for ⁠a ​type ​of lung ​cancer ​missed the main ‌goal ⁠of a ​late-stage ​trial.